Thalidomide-4-O-C2-NH2 hydrochloride

Cat. No.: HY-136162

CAS No.: 2341840-99-9

Molecular Formula: $C_{15}H_{16}ClN_3O_5$

Molecular Weight: 353.76

Target: E3 Ligase Ligand-Linker Conjugates

Pathway: PROTAC

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (353.35 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.8268 mL	14.1339 mL	28.2678 mL
	5 mM	0.5654 mL	2.8268 mL	5.6536 mL
	10 mM	0.2827 mL	1.4134 mL	2.8268 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Thalidomide-4-O-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1].

IC_{50} & Target

Cereblon

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Turk BE, et al. Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A. 1996;93(15):7552-7556.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA